Page last updated: 2024-10-31

mofezolac and Weight Gain

mofezolac has been researched along with Weight Gain in 2 studies

mofezolac: Cyclooxygenase 1 inhibitor; structure in first source; RN from Toxlit

Weight Gain: Increase in BODY WEIGHT over existing weight.

Research Excerpts

ExcerptRelevanceReference
" Toxic signs caused by N-22 administration, observed only in the 200 mg/kg group, were as follows: soiling around the mouth and/or nose, piloerection, anemia, diarrhea, emaciation and decreased spontaneous locomotor activity."1.28[Three-month oral subacute toxicity study of mofezolac (N-22) in rats]. ( Aoki, Y; Hashimoto, Y; Kiguchi, M; Kuwata, M; Okazaki, S; Shimpo, K; Takeuchi, M; Yamashita, K, 1990)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Shimpo, K1
Takeuchi, M1
Okazaki, S1
Kiguchi, M1
Hashimoto, Y1
Aoki, Y1
Kuwata, M1
Yamashita, K1
Yamakita, O1
Koida, M1
Shinomiya, M1
Katayama, S1
Ikebuchi, K1
Yoshida, R1

Other Studies

2 other studies available for mofezolac and Weight Gain

ArticleYear
[Three-month oral subacute toxicity study of mofezolac (N-22) in rats].
    The Journal of toxicological sciences, 1990, Volume: 15 Suppl 2

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Chemical Analysis; Dri

1990
[Reproductive and developmental toxicity study of mofezolac (N-22) (4)--Study by oral administration of N-22 during the perinatal and lactation periods in rats].
    The Journal of toxicological sciences, 1990, Volume: 15 Suppl 2

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Eating; Embryonic and Fetal

1990